| Q54249241 | Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure. |
| Q54308602 | Central and peripheral haemodynamic responses to felodipine in congestive heart failure |
| Q69894427 | Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure |
| Q73940043 | Effects of amlodipine in patients with chronic heart failure |
| Q38152789 | Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders |
| Q68204869 | Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction |
| Q53623270 | Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators. |
| Q42019668 | Reduction of blood pressure by store-operated calcium channel blockers |
| Q73292088 | Vasodilators in the treatment of pediatric heart failure |
| Q54420898 | [Calcium antagonists in heart failure?]. |